| Understanding pharmaceutical quality by design LX Yu, G Amidon, MA Khan, SW Hoag, J Polli, GK Raju, J Woodcock The AAPS journal 16, 771-783, 2014 | 1225 | 2014 |
| Biopharmaceutics classification system: the scientific basis for biowaiver extensions JE Polli, LX Yu, MU Mehta, GL Amidon, H Zhao, LJ Lesko, ML Chen, ... Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation …, 2002 | 912 | 2002 |
| Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers BD Rege, JPY Kao, JE Polli European journal of pharmaceutical sciences 16 (4-5), 237-246, 2002 | 606 | 2002 |
| Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets JE Polli, GS Rekhi, LL Augsburger, VP Shah Journal of pharmaceutical sciences 86 (6), 690-700, 1997 | 465 | 1997 |
| Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach C Acharya, A Coop, J E Polli, A D MacKerell Current computer-aided drug design 7 (1), 10-22, 2011 | 298 | 2011 |
| Biowaiver monographs for immediate release solid oral dosage forms: Diclofenac sodium and diclofenac potassium B Chuasuwan, V Binjesoh, JE Polli, H Zhang, GL Amidon, HE Junginger, ... Journal of pharmaceutical sciences 98 (4), 1206-1219, 2009 | 238 | 2009 |
| Effect of common excipients on Caco-2 transport of low-permeability drugs BD Rege, XY Lawrence, AS Hussain, JE Polli Journal of pharmaceutical sciences 90 (11), 1776-1786, 2001 | 235 | 2001 |
| In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral … JE Polli The AAPS journal 10, 289-299, 2008 | 220 | 2008 |
| Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target A Balakrishnan, JE Polli Molecular pharmaceutics 3 (3), 223-230, 2006 | 202 | 2006 |
| The solute carrier family 10 (SLC10): beyond bile acid transport TC Da Silva, JE Polli, PW Swaan Molecular aspects of medicine 34 (2-3), 252-269, 2013 | 195 | 2013 |
| Rapid identification of P-glycoprotein substrates and inhibitors C Chang, PM Bahadduri, JE Polli, PW Swaan, S Ekins Drug metabolism and disposition 34 (12), 1976-1984, 2006 | 187 | 2006 |
| Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity A Balakrishnan, BD Rege, GL Amidon, JE Polli Journal of pharmaceutical sciences 93 (8), 2064-2075, 2004 | 179 | 2004 |
| The use of BDDCS in classifying the permeability of marketed drugs LZ Benet, GL Amidon, DM Barends, H Lennernäs, JE Polli, VP Shah, ... Pharmaceutical research 25, 483-488, 2008 | 178 | 2008 |
| Summary workshop report: biopharmaceutics classification system—implementation challenges and extension opportunities JE Polli, XY Lawrence, JA Cook, GL Amidon, RT Borchardt, BA Burnside, ... Journal of pharmaceutical sciences 93 (6), 1375-1381, 2004 | 168 | 2004 |
| Influence of passive permeability on apparent P-glycoprotein kinetics KA Lentz, JW Polli, SA Wring, JE Humphreys, JE Polli Pharmaceutical research 17, 1456-1460, 2000 | 148 | 2000 |
| Increased acyclovir oral bioavailability via a bile acid conjugate S Tolle-Sander, KA Lentz, DY Maeda, A Coop, JE Polli Molecular pharmaceutics 1 (1), 40-48, 2004 | 144 | 2004 |
| Lack of medication dose uniformity in commonly split tablets J Teng, CK Song, RL Williams, JE Polli Journal of the American Pharmaceutical Association (1996) 42 (2), 195-199, 2002 | 134 | 2002 |
| Transport of poly amidoamine dendrimers across Madin–Darby canine kidney cells F Tajarobi, M El-Sayed, BD Rege, JE Polli, H Ghandehari International journal of pharmaceutics 215 (1-2), 263-267, 2001 | 131 | 2001 |
| Structure–activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP) Z Dong, S Ekins, JE Polli Molecular pharmaceutics 10 (3), 1008-1019, 2013 | 126 | 2013 |
| Prediction of dissolution–absorption relationships from a dissolution/Caco-2 system MJ Ginski, JE Polli International journal of pharmaceutics 177 (1), 117-125, 1999 | 118 | 1999 |
